Dr. Jeffrey Probstfield Professor of Medicine
School of Medicine
University of Washington
Jeffrey L. Probstfield is a board-certified internist and clinical pharmacologist. He is a former Scientific Project Officer at the National Heart, Lung and Blood Institute for the Systolic Hypertension in the Elderly Program (SHEP), Post-Coronary Artery Bypass Graft (Post-CABG) and Asymptomatic Carotid Artery Progression Study (ACAPS) trials. He is the recipient of the Special Recognition Award from the US public Health Service and the Group Merit Award from the National Institute of Health. He served as the Project Director of the Women's Health Initiative (WHI) Clinical Coordinating Center at the Fred Hutchinson Cancer Research Center between 1993 and 1995. In May 1995 he founded the Clinical Trials Service Unit in the Division of Cardiology at the University of Washington. He currently is Professor of Medicine at the University of Washington School of Medicine (primary alliliation at the University of Washington School of Medicine, Division of Cardiology since 2000), and Adjunct Professor of Epidemiology at the University of Washington School of Public Health. He was one of the eight Regional Coordinators for the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). He served as one of the US Coordinators for the Heart Outcomes Prevention Evaluation (HOPE), and the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) trials. His major areas of interest in research have been in the area of clinical trials methodology, particularly in recruitment and adherence in clinical trials; and in the prevention and treatment of cardiovascular disease, particularly hyperlipidemia, hypertension and congestive heart failure. He currently serves as the US coordinator for the ONTARGET/ TRANSCEND, DREAM, and ORIGIN studies. He joined the staff at the Southwest Oncology Group (SWOG) Coordinating Center as a physician consultant in June of 1995 and has been involved in two prostate cancer prevention trials [Prostate Cancer Prevention Trial, PCPT; 18,881 participants, finasteride versus nil (results recently in NEJM) and Selenium and Vitamin E Chemoprevention Trial, SELECT; projected 32,000, selenium versus nil factorial with Vitamin E versus nil]. He currently leads one of the seven Clinical Center Networks in NHLBI's Prevention of Cardiovascular Disease in Diabetics (ACCORD), and has recently been funded as the Principal Investigator of the K-30 Training Grant for the University of Washington.
